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Background: The primary objective of this study is to describe variations in incidence rates, resection rates, and
types of surgical ablations performed on patients diagnosed with major salivary gland cancers in Ontario.
Methods: All major salivary gland cancer cases in Ontario (2003–2010) were identified from the Ontario Cancer
Registry (n = 1,241). Variations in incidence rates, resection rates, and type of surgical therapy were compared by
sex, age group, neighbourhood income, community population, health region, and physician specialty.
Results: Eight-year incidence rates per 100,000 vary significantly by sex (male: 15.5, female: 9.7), age (18–54 years:
6.7, 75+ years: 53.4), neighborhood income (lowest quintile: 11.8, highest quintile: 13.7), and community size (cities
with a population greater than 1.5 million: 10.6, cities with a population of less than 100,000: 14.7). There was a
significant correlation between the likelihood to receive a resection and age with the elderly (75+ years) being the
least likely to receive resection (69%). Large differences in incidence and resection rates were observed by health
region. Otolaryngology-Head & Neck surgeons provide the majority of total/radical resections (95%).
Conclusions: Major salivary gland cancer incidence rates vary by sex, age, neighborhood income, community size,
and health region. Resection rates vary by age and health region. These disparities warrant further evaluation.
Otolaryngology-Head & Neck Surgeons provide the majority of major salivary gland cancer surgical care.
Keywords: Health services research, Health policy, Salivary gland cancer, Head and neck oncologyBackground
Malignant tumours of the salivary glands have a rela-
tively low incidence as compared to other head and neck
cancers. In 2007, 419 new cases of salivary gland cancer
were identified in Canada, 230 of which occurred in
males [1]. In 2009, 109 deaths were attributable to saliv-
ary gland cancer in Canada [1]. U.S. data suggest that
the incidence of salivary gland cancers appears to have
slightly increased over the last three decades while saliv-
ary gland cancer-related deaths have not significantly de-
creased [2-4]. Salivary gland cancers account for more
than 0.5% of all malignancies and approximately 7% of
all head and neck cancers [5]. They present largely in* Correspondence: david.goldstein@uhn.ca
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multidisciplinary care, and have diverse histology.
The mainstay of treatment is surgical resection with
post-operative radiotherapy for those with high risk dis-
ease. Distribution and variations in surgical care for major
salivary gland cancer (parotid and submandibular) in
Ontario, Canada's most populated province with a well
organized cancer program, has not been studied since 1997
[6]. This information is critical to support population-
based, regional planning of Ontario's cancer surgical
services, and to provide background information for
provincial quality improvement initiatives in the field of
head and neck oncology. The objectives of this study
were to describe the incidence of major (parotid and
submandibular) salivary gland cancers, and demon-
strate the variations in surgical care and hospital level
determinants.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Data sources
All malignancies of the parotid and submandibular
glands were identified in the Ontario Cancer Registry
(ICD-9 diagnosis codes: 142.0, 142.1). Validation studies
have shown that the OCR is effective at ascertaining
cancer cases (98% sensitivity) [7] and specifically for
head and neck cancer identifies the cancer site accur-
ately in 91% of primary cases [8]. All non-lymphoma
histological types were included according to the ICD-
O-3 histology codes. Patients with melanoma were ex-
cluded, however, none were detected in our cohort prior
to applying exclusion criteria. Despite there being no de-
tected melanoma metastases to the parotid or submandibu-
lar gland being miscoded as primary tumours, metastases
of unknown primary skin cancers are not distinguishable
from primary squamous cell carcinoma of the salivary gland
in the registry and, since surgery is the mainstay of
treatment for both situations, we included both in this
study. Incident major salivary gland cancers cases from
the OCR were linked to the Canadian Institute for
Health Information Discharge Abstract Database (CIHI
DAD) and CIHI Same Day Surgery (SDS) Database
using relevant salivary gland and submandibular gland
resection codes providing hospital level information.
To further ascertain resection, we linked incident head
and neck cancer cases from the OCR to Ontario Health
Insurance Plan (OHIP) data through which the vast ma-
jority of physicians are remunerated for their surgical
cases. The OHIP database also provides a unique surgeon
identifier which can be linked to the ICES Physician
Database (IPDB) to provide information about the phy-
sicians performing salivary gland cancer resection in-
cluding specialty, year of graduation, and gender. The
study protocol was approved by the Privacy Office at
the Institute for Clinical Evaluative Sciences (ICES) and
by the Research Ethics Board of Sunnybrook Health
Sciences Centre.
Study subjects
All Ontario men and women 18 years of age or older
who were diagnosed with a non-lymphoma salivary
gland cancer between January 1, 2003 and December 31,
2010 were identified in the Ontario Cancer Registry
(OCR). This cohort will be referred to as the Overall
Salivary Gland Cancer Cohort. From this cohort all pa-
tients undergoing resection of the primary tumour site
within 12 months before or after their diagnosis date
were identified. This cohort will be referred to as the
Salivary Gland Resection Cohort. A restrictive resection
definition was used to increase confidence in the valid-
ity of the resection cohort. For inclusion in the final re-
section cohort, a patient had to meet the following
criteria [1]: identification of their cancer in OCR [2];resection in CIHI-DAD or SDS databases [3]; resection
in OHIP database; and [4] resection dates in CIHI and
OHIP must have been within 7 days of each other.
After having identified patients with a resection in
CIHI-DAD or SDS and then linking to resection codes
in OHIP, approximately 10% of patients did not have
matching codes. We also performed the reverse and
started with OHIP codes and then linked to CIHI-DAD
or SDS codes and found that 10% of patients did not have
a matching code. As is customary at ICES, we chose to
start with CIHI codes as they are considered more reliable.
Patients missing key demographic data and those with a
prior diagnosis of cancer were excluded.
Exposures
The following variables were included as important de-
scriptive covariates; sex, age at time of diagnosis, so-
cioeconomic status based on postal code income
census data, and community size (>1,500,000; 100,000-
1,499,999; and <100,000). Ontario's 14 Local Health
Integration Networks (LHINs) which are smaller geo-
graphic regions that integrate and distribute health
care resources locally, were also used to assess varia-
tions in incidence and surgical resection rates.
Ontario has a very highly regionalized head and neck
oncology program with 9 hospitals in 6 cities providing
the majority of the care, including radiation oncology
therapy. These hospitals are well known to the study au-
thors and were designated as head and neck cancer cen-
tres. This designation of hospital (head and neck cancer
centre or not) was used as a study covariate. Lastly, phy-
sicians performing salivary gland cancer surgery were
identified by their specialty type, namely, general sur-
gery, plastic surgery, or otolaryngology - head & neck
surgery. The specialty designation was determined using
the IPDB and OHIP databases. Variations in the use of
neck dissection and radiotherapy by LHIN of residence
at the time of diagnosis and LHIN of treatment were
also examined.
Outcomes
Incidence rates are presented as 8-year age-standardized in-
cidence rates per 100,000 population. All incidence rates
were standardized to the 1991 population of Canada as of
July 1, 1991, a year commonly used for analyses of Canadian
health data, using the direct method of standardization.
Variations in resection rates were assessed for each of
the covariates previously described. Finally, the CIHI
coding (CCI - Canadian Classification for Health Inter-
ventions) for partial resection as opposed to total or
radical resection was used to assess differences amongst
surgical specialty treating salivary gland malignancies
and hospitals in which the procedures were performed.
OHIP codes have been found to be inaccurate at
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used CIHI codes (CCI - Canadian Classification for
Health Interventions) which have been validated for
many procedures and have been demonstrated to be far
more accurate [9]. The CIHI codes (CCI - Canadian
Classification for Health Interventions) used to desig-
nate a parotidectomy as radical involve closure of the
defect with some form of a reconstructive technique
and include both nerve sparing and non-sparing tech-
niques. The remaining CIHI codes for parotidectomy
describe a total resection versus a partial resection. We
found that extent of parotidectomy from OHIP and
CIHI codes were well correlated, that is, more than
90% of OHIP-coded superficial parotidectomies were
coded as partial resections whereas OHIP-coded total
procedures were coded as either total or radical paroti-
dectomies in CIHI. Because CIHI resection codes (CCI -
Canadian Classification for Health Interventions) have
been shown to be more accurate, CIHI codes were used.
We separated resections as either partial/subtotal or total/
radical based on the description provided by CIHI. This
applied to both the parotid and submandibular sites and is
a measure of extent of resection as coded by CIHI coders.
This was used assess whether extent of resection differed
by physician specialty and hospital type.
Statistical analysis
Descriptive analyses are presented by age, gender,
neighborhood income quintile, community size, hos-
pital type, surgeon specialty and LHIN. Differences in
proportions were tested using the chi square test. For
ordinal variables, the Mantel-Haenszel Chi Square was
used to assess for trend. Statistical significance was de-
fined by a two-sided p-value of 0.05. All analyses were
performed using SAS version 9.2 (SAS Institute, Cary,
North Carolina).Figure 1 Salivary gland cancer histology 2003–2010.Results
The distribution of histological diagnoses is presented in
Figure 1. There were no metastatic melanoma skin can-
cers incorrectly coded as primary parotid or subman-
dibular gland malignancies. However, 22% of our cohort
had squamous cell carcinoma diagnosis.
Salivary gland incidence
Major salivary gland cancer incidence and surgical resec-
tion rates by demographic variables are presented in
Table 1. Major salivary gland cancers were more com-
mon in males (15.5 per 100,000) and in the older age
categories, particularly in those above the age of 70 (30.9
per 100,000 for 70–74 years and 53.4 per 100,000 for
those 75 years or over). There were higher incidence
rates in higher neighborhood income groups (highest
quintile 13.7 per 100,000). There were also higher inci-
dence rates in larger communities (14.7 per 100,000).
Surgical resection rates and type of resection
Overall, 82% of patients received a surgical resection for
their major salivary gland cancer. Resection rates did not
vary significantly by sex, however, women were statistically
more likely to receive a partial resection as opposed to a
radical resection. Increasing age was associated with a sta-
tistically significant lower likelihood of receiving a surgery.
Radical resection rates did not differ by age category, how-
ever, elderly patients (i.e. patients over 75 years of age)
were less likely to receive a partial or subtotal resection
compared to younger patients. Neighborhood income and
community size did not predict likelihood of receiving a
surgical procedure or extent of surgery.
LHIN variations
There were significant variations (p < 0.001) in major sal-
ivary gland cancer incidence rates between Ontario's 14











n (%) % Total % Total
Sex
Female 507 (40.9) 9.7 83.6 43.6 40.0
Male 733 (59.1) 15.5 79.9 35.7 44.2
P < 0.0001 P = 0.10 P = 0.005 P = 0.15
Age Group
18-54 years 409 (33.0) 6.7 91.4 50.1 41.3
55-64 years 246 (19.8) 18.2 82.9 41.5 41.5
65-69 years 92 (7.4) 19.9 83.7 41.3 42.4
70-74 years 122 (9.8) 30.9 81.1 32.8 48.4
75+ years 371 (29.9) 53.4 69.0 26.4 42.6
P < 0.0001 P < 0.0001 P < 0.0001 P = 0.78
Neighborhood income
1 – Lowest 240 (19.4) 11.8 74.6 34.6 40.0
2 202 (16.3) 9.5 83.7 41.6 42.1
3 260 (21.0) 12.9 82.7 40.0 42.7
4 259 (20.9) 12.6 83.0 39.8 43.2
5 – Highest 279 (22.5) 13.7 83.2 39.1 44.1
P < 0.0001 P = 0.08 P = 0.67 P = 0.78
Community population
≥ 1,500,000 428 (34.5) 10.6 82.0 38.1 43.9
100,000-1,499,999 474 (38.2) 12.1 82.7 41.4 41.4
< 100,000 338 (27.3) 14.7 79.0 36.7 42.3
P < 0.0001 P = 0.44 P = 0.41 p = 0.77
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year standardized incidence rate of 6.4 per 100,000 while
LHIN 12 had a rate of 13.3 per 100,000. There was also
variability between LHINs of residence at time of treat-
ment in terms of surgical resection rates with patients in
LHIN 10 having the lowest resection rate (71.7%) and
LHIN 8 having the highest (88.5%). This variation was
less pronounced than the variation in incidence rates.
Surgical resection rates and incidence rates were not
correlated. Some LHINs had relatively lower incidence
rates with very high resection rates, such as LHIN 5,
while some had high incidence rates with relatively low
resection rates, such as LHIN 12.
Surgeon specialty
Plastic surgeons, general surgeons, and otolaryngologist-
head & neck surgeons constituted 4.5%, 15.7%, and
79.9% of surgeons/physicians performing major saliv-
ary gland cancer surgery in the province respectively.
Plastic surgeons and general surgeons performed a
relatively smaller proportion of surgeries 0.74% and
8.5% respectively, as compared to otolaryngologist-head & neck surgeons (90.8%; Figure 3) who operated
on the vast majority of patients. Otolaryngologist-head
& neck surgeons performed more (94.7%) total or rad-
ical resections as compared to plastic surgeons (0.20%)
and general surgeons (5.1%).
Hospital type
The nine designated head and neck cancer centres in
Ontario represented only 14.5% of the hospitals perform-
ing major salivary gland cancer surgery in the province.
There were an additional 53(85.5%) hospitals performing
salivary gland cancer surgery. The head and neck cancer
centres provided care to a disproportionate number of
cases, operating on 57.4% of our patient cohort. Further-
more, these centres were far more likely to perform total
or radical resections (60.3% of their cases) as compared to
other centres (only 41.2% of their cases) (Table 2).
Neck dissection and post-operative radiotherapy by LHIN
of residence and treatment
There were some variations noted in the use of neck
dissection and radiotherapy by LHIN of residence and
Figure 2 Salivary gland cancer 8-year incidence and percentage of cases receiving resection within 1 year of diagnosis by Local Health
Integration Network (LHIN) of residence at diagnosis.
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tients that received a resection also received a neck dis-
section. Patients residing in LHIN 12 at the time of
their diagnosis received the most neck dissections
(62.5%) while those in LHIN 10 had the lowest neck
dissection rates (37.2%); however, differences in neck
dissection by LHIN of residence were not statistically
significant (p-value 0.21). On average, 59.3% of patients
that received a resection also received radiotherapy.Figure 3 Percentage of physicians, surgeries, patients, and procedurePatients residing in LHIN 14 at the time of their diag-
nosis were most likely to receive radiotherapy (77.2%)
while those in LHIN 10 were least likely to have re-
ceived radiotherapy (46.5%); however, differences in
radiotherapy use by LHIN of residence were not statisti-
cally significant (p-value 0.16). More dramatic variations
in neck dissection (p-value <0.001) and radiotherapy rates
(p-value <0.001) were noted by LHIN of treatment
(Table 4).s by specialty.
Table 2 Salivary gland cancer pattern of surgical care by
hospital type
Definitive procedure by hospital type
Hospital
type




N (% total) n (% resections) n (% resections)
Head & neck
cancer centre
580 (57.4) 39.7 60.3
Other 430 (42.6) 58.8 41.2
P-value <0.0001
Total 1010 (100) 47.8 52.2
Table 4 Variations in the use of neck dissection and
post-operative radiotherapy by LHIN of treatment




Resection cohort 1010 49.2 59.3
LHIN 1 22 27.3 40.9
LHIN 2 160 52.5 58.8
LHIN 3 33 21.2 42.4
LHIN 4 125 50.4 55.2
LHIN 5 28 28.6 50.0
LHIN 6 55 43.6 50.9
LHIN 7 281 73.3 69.4
LHIN 8 33 18.2 57.6
LHIN 9 82 28.0 50.0
LHIN 10 27 18.5 40.7
LHIN 11 87 40.2 65.5
LHIN 12 18 27.8 44.4
LHIN 13 45 51.1 68.9
LHIN 14 14 14.3 64.3
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Major salivary gland cancer incidence increases with age.
The elderly represent nearly 40% of those with major
salivary gland cancer in our cohort and are far less likely
to receive surgical resection. The mainstay of treatment
for major salivary gland cancers remains surgical resec-
tion with or without post-operative radiotherapy. The
elderly are likely to have more comorbidities, are much
more likely to experience acute medical complications (OR
3.7), in-hospital death (OR 3.6), increased hospitalization
(by a mean of 2.2 days), and increased hospital-related
costs (by a mean of $6,874 US) as demonstrated using a
cohort of head and neck cancer patients derived from the
Nationwide Inpatient Sample [10]. Also, elderly patients
treated for major salivary gland cancer have a poorer prog-
nosis independent of treatment [11]. For these reasons,
surgical treatment may be precluded more often in the eld-
erly patients.Table 3 Variations in the use of neck dissection and
post-operative radiotherapy by LHIN of residence




Resection Cohort 1010 49.2 59.3
LHIN 1 60 50.0 56.7
LHIN 2 109 47.7 55.0
LHIN 3 61 47.5 55.7
LHIN 4 113 46.9 57.5
LHIN 5 46 43.5 60.9
LHIN 6 79 53.2 46.8
LHIN 7 67 56.7 62.7
LHIN 8 101 58.4 62.4
LHIN 9 136 44.9 61.0
LHIN 10 43 37.2 46.5
LHIN 11 78 39.7 65.4
LHIN 12 40 62.5 67.5
LHIN 13 55 56.4 69.1
LHIN 14 22 45.5 77.3Major salivary gland cancer incidence was also associ-
ated with increasing neighbourhood income quintile and
smaller community size, a finding which has never been
previously reported in the medical literature. This is the
opposite of trends described for mucosal head and neck
malignancies [12,13]. It has been demonstrated that
Caucasians are more likely to develop major salivary
gland cancer than other racial groups, and this measure
of socioeconomic status could potentially be related to
race, a variable not available in Canadian health adminis-
trative databases [4]. Certain occupations are however
associated with salivary gland cancer including rubber
products manufacturing, asbestos mining, plumbing and
some types of woodworking [14]. There has been no de-
finitive evidence in the literature that major salivary
gland cancer or that any cancer for that matter, is related
to cell phone use [15,16], however, given the location of
these glands, and the higher incidence in higher socio-
economic groups, this may warrant further study.
There are significant variations by geographic region
of residence (ie. LHIN) with regards to incidence, resec-
tion rates, neck dissection and radiotherapy use. The
variation in incidence across geographic region may be
due to a variety of etiologies which our current dataset
is unable to capture including varying infection rates,
environmental exposures, carcinogenic exposures or this
may be due to confounding by our inclusion of meta-
static skin squamous cell carcinoma. It is worth noting
that these variations are striking and significantly greater
than for other cancers in our province [9]. The varia-
tions in neck dissection and radiotherapy use may be
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ease but such large variations merit further study. Patho-
logical staging data is starting to become available and
will be the subject of future research which may help an-
swer this question.
Our data suggest that the management of salivary
gland cancers in Ontario is far less regionalized than for
oral cavity and larynx/hypopharynx cancer. For both of
these latter subsites, greater than 90% of cases are per-
formed at head and neck cancer centres as compared to
the 57% demonstrated for salivary gland cancers. We
have previously reviewed volume-outcome studies in the
field of head and neck oncology, and concluded that
there lacked evidence for such a relationship in the
treatment of major salivary gland cancers [17]. Despite
ultrasound-guided fine needle aspiration and trained cy-
tologists, a significant proportion of salivary gland lesions
are excised without a pre-operative tissue diagnosis and
are thus performed for diagnostic and therapeutic pur-
poses. Ultrasound-guided fine needle aspiration and ad-
vanced cytological diagnosticians are not readily available
in many regions in the province of Ontario and this may
affect surgeons’ ability to pre-operatively plan the extent
of resection. However, the data on neck dissection and
radiotherapy by region (ie. LHIN) of treatment demon-
strates much higher rates of both of these interventions in
regions with a head and neck cancer centre. This suggests
that advanced and/or aggressive tumours, based on
clinical and radiological grounds, are being appropri-
ately referred to high volume centres for resection and
subsequent management. Although the preliminary
data suggests this, further study is required to confirm
whether this is indeed the case as this was not the pri-
mary objective of our study. Pathologic and staging data
which is becoming increasingly available in our datasets
will help elucidate this. Given the rarity of these tu-
mours, their varied histologies and the current lack of
regionalization as compared to the management of
other head and neck cancer subsites, a policy to further
regionalize the treatment of these tumours may be
warranted.
These data must be interpreted in the context of the
study design. The most important limitation of this
study is the possibility of the OCR having misidentified
skin squamous cell carcinoma metastatic to the parotid
gland as primary parotid gland malignancies. Although
this is possible, we do not feel that this changes the im-
portance of our findings, which in the context of a uni-
versal health care system have significant implications.
Also, this weakness is mitigated by the fact that patients
with skin squamous cell carcinomas in close proximity
to or metastatic to the parotid may receive a parotidect-
omy and neck dissection with or without adjuvant treat-
ment, a similar treatment paradigm to most primaryparotid malignancies. Nonetheless, the squamous cell
carcinoma histology may have significant impacts on our
variations by LHIN of residence as some of the regions
with the highest incidence rates are largely Caucasian,
and have a higher population of outdoor workers (e.g.
farmers), important risk factors for sun-induced skin
cancers. Another important limitation is our inability to
determine resection rates by LHIN of treatment since
we have little data on those patients that did not receive
surgical resection, limiting our ability to determine a de-
nominator (ie. total number of patients presenting with
cancer) for each LHIN of treatment.
Our study has a number of strengths. The OCR has a
much higher cancer capture rate than the two most
commonly used U.S. databases (SEER and NCDB; 26%
and 70% respectively). This makes the OCR more repre-
sentative of Ontario patients than SEER or NCDB for U.
S. populations. This study is the largest series in the lit-
erature describing important sociodemographic factors
in major salivary gland cancer patients. A number of key
variations have been identified, which raises concerns
around equitable treatment of patients with salivary
gland cancer across our province and these merit further
inquiry with the aim of reducing such variations. This
type of overview is particularly useful for policy makers
and health administrators as resources are organized
and is the first step towards improving access and qual-
ity of care.
Our findings have important implications for policy
makers as it relates to two of Canada Health Act's key
tenants; universality and equitability. Surgery remains
the mainstay of treatment for major salivary gland can-
cers. There appears to be a relatively low resection rates
in certain regions (LHINs) and in certain populations
(the elderly). These findings require further investigation but
raise important questions about access to Otolaryngology -
Head & Neck surgery expertise in our province. Certain
LHINs have lower resection rates and one possible hy-
pothesis is lack of access to major salivary gland cancer
surgery expertise. Similarly, further study is required to
determine the appropriateness of lower resection rates
in the elderly. Although these resection rates may be
appropriate, given our aging population and the higher
incidence of major salivary gland cancers in the elderly,
this will be an ongoing equitability concern.
Conclusion
Major salivary gland cancer incidence rates vary by sex,
age, neighborhood income, community size, and health
region. Resection rates vary by age and health region.
These disparities warrant further evaluation to deter-
mine whether there is access inequity and whether there
are quality of care improvements that can be made in
this area of care.
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de-identified data was used.
Abbreviations
OCR: Ontario cancer registry; CIHI: Canadian Institute for Health Information;
OHIP: Ontario health insurance plan; ICES: Institute for Clinical Evaluative
Sciences; IPDB: ICES Physician Database.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AE JI JF DRU and DPG participated in the conception and design of the
project. AE and DRU were involved in the acquisition of the data. AE JI PG
RG PAG SFH DRU DPG were involed in the analysis and interpretion of the
data. AE JI DRU DPG were involved in drafting the manuscript. All authors
were involved in revisiting the manuscript critically for important intellectual
content. All authors gave final approval of the version to be published. All
authors agree to be accountable for all aspects of the work.
Authors’ information
Dr. Antoine Eskander was supported by funding from the Chapnik, Freeman
and Friedberg Surgeon Scientist Award, the Temmy Latner/Dynacare Chair in
Head and Neck Oncology Fund at Mount Sinai Hospital, the Estey Fund from
the Princess Margaret Hospital Foundation, the Kevin and Sandra Sullivan
Chair in Surgical Oncology Fund and Department of Otolaryngology – Head
and Neck Surgery at the University Health Network.
David R Urbach and David P Goldstein are co-senior authors.
Acknowledgements
This study was supported by the Institute for Clinical Evaluative Sciences
(ICES), which is funded by an annual grant from the Ontario Ministry of
Health and Long-Term Care (MOHLTC). The opinions, results and conclusions
reported in this paper are those of the authors and are independent from
the funding sources. No endorsement by ICES or the Ontario MOHLTC is
intended or should be inferred.
Financial support
Dr. Antoine Eskander was supported by funding from the Chapnik, Freeman
and Friedberg Surgeon Scientist Award, the Temmy Latner/Dynacare Chair in
Head and Neck Oncology Fund at Mount Sinai Hospital, the Estey Fund from
the Princess Margaret Hospital Foundation, the Kevin and Sandra Sullivan
Chair in Surgical Oncology Fund and Department of Otolaryngology – Head
and Neck Surgery at the University Health Network.
Author details
1Department of Otolaryngology – Head and Neck Surgery, University of
Toronto, Toronto, ON, Canada. 2Department of Otolaryngology – Head and
Neck Surgery, Department of Surgical Oncology, Princess Margaret Cancer
Centre, Toronto, ON, Canada. 3Department of Otolaryngology – Head and
Neck Surgery, Mount Sinai Hospital, Toronto, Ontario, Canada. 4Cancer Care
and Epidemiology Division, Queen’s Cancer Research Institute, Queen’s
University, Kingston, ON, Canada. 5Department of Otolaryngology – Head
and Neck Surgery, Queen’s University, Kingston, ON, Canada. 6Division of
General Surgery, Department of General Surgery and Surgical Oncology,
University of Toronto, Toronto, ON, Canada. 7Department of Otolaryngology –
Head & Neck Surgery, University Health Network, Princess Margaret Hospital,
610 University Ave., Rm 3-952, Toronto M5G 2M9, ON, Canada.
Received: 15 July 2014 Accepted: 25 November 2014
References
1. Canadian cancer statistics [Internet]. Toronto, ON: Canadian Cancer Society;
2013. [updated May, 2013; cited March 15, 2014]. Available from: http://www.
cancer.ca/en/en/cancer-information/cancer-type/salivary-gland/statistics/?
region=ns.2. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP: Trends in incidence
and prognosis for head and neck cancer in the united states: a site-
specific analysis of the SEER database. Int J Cancer 2005, 114(5):806–1.
3. Davies L, Welch HG: Epidemiology of head and neck cancer in the United
States. Otolaryngol Head Neck Surg 2006, 135(3):451–457.
4. Boukheris H, Curtis RE, Land CE, Dores GM: Incidence of carcinoma of the
major salivary glands according to the WHO classification, 1992 to 2006:
a population-based study in the United States. Cancer Epidemiol
Biomarkers Prev 2009, 18(11):2899–2906.
5. Speight PM, Barrett AW: Salivary gland tumours. Oral Dis 2002, 8(5):229–240.
6. Iscoe NA, To T, Gort EH, Tran M: Cancer Surgery in Ontario. Toronto: Institute
for Clinical Evaluative Sciences; 1997.
7. McLaughlin JR, Kreiger N, Marrett LD, Holowaty EJ: Cancer incidence
registration and trends in ontario. Eur J Cancer 1991, 27(11):1520–1524.
8. Hall S, Schulze K, Groome P, Mackillop W, Holowaty E: Using cancer
registry data for survival studies: the example of the Ontario cancer
registry. J Clin Epidemiol 2006, 59(1):67–76.
9. Urbach DR, Simunovic M, Schultz SE: Cancer Surgery in Ontario: ICES Atlas.
Toronto: Institute for Clinical Evaluative Sciences; 2008.
10. Genther DJ, Gourin CG: The effect of comorbidity on short-term outcomes
and cost of care after head and neck cancer surgery in the elderly. Head
Neck 2014. doi: 10.1002/hed.23651. [Epub ahead of print]
11. Chen MM, Roman SA, Sosa JA, Judson BL. Prognostic factors for squamous
cell cancer of the parotid gland: An analysis of 2,104 patients. Head Neck
2013. doi: 10.1002/hed.23566. [Epub ahead of print]
12. Bradley PJ, McGurk M: Incidence of salivary gland neoplasms in a defined
UK population. Br J Oral Maxillofac Surg 2013, 51(5):399–403.
13. Hwang E, Johnson-Obaseki S, McDonald JT, Connell C, Corsten M: Incidence
of head and neck cancer and socioeconomic status in canada from 1992
to 2007. Oral Oncol 2013, 49(11):1072–1076.
14. Ellis GL, Auclair PL: Tumors of the Salivary Glands. 3rd ed. Armed Forces Institute
of Pathology, Editor. Washington, DC: Atlas of Tumor Pathology; 1996.
15. Lönn S, Ahlbom A, Christensen HC, Johansen C, Schüz J, Edström S,
Henriksson G, Lundgren J, Wennerberg J, Feychting M: Mobile phone use
and risk of parotid gland tumor. Am J Epidemiol 2006, 164(7):637–643.
16. Schuz J, Jacobsen R, Olsen JH, Boice JD Jr, McLaughlin JK, Johansen C:
Cellular telephone use and cancer risk: update of a nationwide Danish
cohort. J Natl Cancer Inst 2006, 98(23):1707–1713.
17. Eskander A, Merdad M, Irish JC, Hall SF, Groome PA, Freeman JL, Urbach DR,
Goldstein DP: Volume-outcome associations in head and neck cancer
treatment: a systematic review and meta-analysis. Head Neck 2013,
36(12):1820–34.
doi:10.1186/s40463-014-0050-6
Cite this article as: Eskander et al.: Overview of major salivary gland
cancer surgery in Ontario (2003–2010). Journal of Otolaryngology - Head
and Neck Surgery 2014 43:50.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
